Completed PHASE2 INTERVENTIONAL NCT00005935

Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia

A Randomized Trial for the Treatment of Relapsing Aplastic Anemia With Mycophenolate Mofetil (MMF) and Cyclosporine (CSA)

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Aplastic Anemia

Interventions Cyclosporine Mycophenolate mofetil

Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Jun 30, 2000 Completion: Mar 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Aplastic Anemia, this trial is completed. The trial is conducted by National Heart, Lung, and Blood Institute (NHLBI) and has accumulated 5 data snapshots since 2000. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Heart, Lung, and Blood Institute (NHLBI)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States